Diffuse large b cell lymphoma associated with unspecified Epstein Barr virus: review of the literature
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.153.1698Keywords:
Lymphoma, virus, Epstein Barr, prognosis, Lymphoma, Large B-Cell, Diffuse , Herpesvirus 4, HumanAbstract
Diffuse Large B-Cell Lymphoma associated with Epstein Barr virus Not otherwise specified is a frequent entity in South America, which affects patients of all ages but more frequently senile patients. Diagnosis is through the identification of the Epstein Barr virus within the tumor cell using the EBER test. The prognosis is unfavorable despite having improved with the introduction of rituximab. There are new prognostic scores for the identification of risk subgroups. The treatment continues to be the same as for cases of Epstein Barr virus-negative diffuse Large B-Cell Lymphoma. New novel therapeutic strategies against this entity are expected.
Downloads
Metrics
References
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2.
Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27(1):16-26. doi: 10.1097/00000478-200301000-00003.
Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13(17):5124-32. doi: 10.1158/1078-0432.CCR-06-2823.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-32. doi: 10.1182/blood-2011-01-293050.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. doi: 10.1182/blood-2016-01-643569
Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, et al. Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol. 2011;83(2):317–21. doi: 10.1002/jmv.21967.
Chang ST, Lu YH, Lu CL, Weng SF, Lin SH, Kuo SY, et al. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol. 2014;67(4):326–32. doi: 10.1136/jclinpath-2013-201905.
- Beltran BE, Castillo JJ, Morales D, De Mendoza FH, Quinones P, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. Am J Hematol. 2011;86(8):663–7. doi: 10.1002/ajh.22078.
Uner A, Akyurek N, Saglam A, Abdullazade S, Uzum N, Onder S, et al. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on ‘EBV-positive DLBCL of the elderly’. APMIS. 2011;119(4–5):309–16. doi: 10.1111/j.1600-0463.2011.02736.x.
Stuhlmann-Laeisz C, Borchert A, Quintanilla-Martinez L, Hoeller S, Tzankov A, Oschlies I, et al. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma. 2016;57(1):39–44. doi: 10.3109/10428194.2015.1040014.
Young LS, Yap LF, Murray PG. Epstein-Barr virus: More than 50 years old and still providing surprises. Nature Reviews Cancer. 2016;16(12): 789–802. doi: 10.1038/nrc.2016.92
Shibusawa M, Kidoguchi K, Tanimoto T. Epstein-Barr Virus-Positive Diffuse Large B Cell Lymphoma. Lymphoma. 2021[cited 2022 Feb 7]; 27-46. Available from: https://bit.ly/3fFtaFJ
Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosía SG, Mazorra F, et al. EBVpositive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968–82. doi: 10.1038/modpathol.2012.52.
Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019;103(3):200–7. doi: 10.1111/ejh.13274
Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;33(7):1687–99. doi: 10.1038/s41375-019-0380-5.
- Zhao CX, Wen JJ, Fu D, Xu PP, Cheng S, Wang L, et al. J. Clinical and molecular features of Epstein-Barr virus-positive diffuse large B-cell lymphoma: Results in a multi-center trial. Clin Transl Med. 2021;11(9):e539. doi: 10.1002/ctm2.539
- Zhou Y, Xu Z, Lin W, Duan Y, Lu C, Liu W, et al. Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. Front Oncol. 2019;9:683. doi: 10.3389/fonc.2019.00683.
- Gebauer N, Künstner A, Ketzer J, Witte HM, Rausch T, Benes V, et al. Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. Blood Cancer J. 2021;11(5):102. doi: 10.1038/s41408-021-00493-5.
Beltran BE, Quiñones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, et al. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018;36(1):93–7. doi: 10.1002/hon.2449.
Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019;103(3):200–7. doi: 10.1111/ejh.13274
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(7):953–62. doi: 10.1002/ajh.25112.
Ohashi A, Kato S, Okamoto A, Inaguma Y, Satou A, Tsuzuki T, et al. Reappraisal of Epstein-Barrvirus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparativeanalysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. Histopathology.2017;71(1):89–97. doi: 10.1111/his.13197.
Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res. 2000;91(12):1233–40. doi: 10.1111/j.1349-7006.2000.tb00909.x.
Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, et al. Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol. 2011;83(2):317–21. doi: 10.1002/jmv.21967.
Chang ST, Lu YH, Lu CL, Weng SF, Lin SH, Kuo SY, et al. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol. 2014;67(4):326–32. doi: 10.1136/jclinpath-2013-201905.
Beltran BE, Castillo JJ, Morales D, De Mendoza FH, Quinones P, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. Am J Hematol. 2011;86(8):663–7.
Stuhlmann-Laeisz C, Borchert A, Quintanilla-Martinez L, Hoeller S, Tzankov A, Oschlies I, et al. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma. 2016;57(1):39–44. doi: 10.3109/10428194.2015.1040014.
D. Castro, BE Beltran,L. Villela,E. Montaño ,A. Ramirez-Ibarguen, M. Candelaria et al. Clinicopathological Features and Outcomes of EBV Positive and Negative DLBCL: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood. 2021; 138 (Sup 1): 1442. Doi: 10.1182/blood-2021-152340
Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug;86(8):663–7.
Gao X, Li J, Wang Y, Liu S, Yue B. Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis. PLoS One. 2018;13(6):1–13. Doi: 10.1371/journal.pone.0199398
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94. doi: 10.1056/NEJM199309303291402.
Witte HM, Merz H, Biersack H, Bernard V, Riecke A, Gebauer J, et al. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma. Br J Haematol. 2020 Apr;189(2):257-268. doi: 10.1111/bjh.16342
Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5: 12168. doi: 10.1038/srep12168.
Ziarkiewicz M, Wołosz D, Dzieciątkowski T, Wilczek E, Dwilewicz-Trojaczek J, Jędrzejczak WW, et al. Epstein–Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland. Arch Immunol Ther Exp (Warsz). 2016;64(2):159–69. doi: 10.1007/s00005-015-0341-2.
BE Beltran, D. Castro, L. Villela, E. Montaño, F. Ana Ramirez-Ibarguen, M. Candelaria, et al. A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood. 2021; 138 (Sup 1): 1436. Doi: 10.1182/blood-2021-151389.
B eltran BE, Quiñones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, et al. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018;36(1):93–7. doi: 10.1002/hon.2449.
Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(7):951-965. doi: 10.1002/ajh.26579.
Kim SJ, Hyeon J, Cho I, Ko YH, Kim WS. Comparison of efficacy of pembrolizumab between Epstein-Barr virus-positive and -negative relapsed or refractory non-hodgkin lymphomas. Cancer Res Treat. 2019;51(2):611–22.
Crombie JL, LaCasce AS. Epstein Barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders. Front Oncol. 2019;9:1–9. doi: 10.3389/fonc.2019.00109.
Hui KF, Chiang A. Suberoylanilide Hydroxamic Acid Induces Viral Lytic Cycle in Epstein-Barr Virus-Positive Epithelial Malignancies and Mediates Enhanced Cell Death. Int J Cancer. 2010;126(10):2479-89. doi: 10.1002/ijc.24945.
Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao G, Chiang A. Activation of Lytic Cycle of Epstein-Barr Virus by Suberoylanilide Hydroxamic Acid Leads to Apoptosis and Tumor Growth Suppression of Nasopharyngeal Carcinoma. Int J Cancer. 2012;131(8):1930-40. doi: 10.1002/ijc.27439.
Kawanishi M. Epstein-Barr Virus Induces Fragmentation of Chromosomal DNA During Lytic Infection. J Virol. 1993; 67(12): 7654–7658. doi: 10.1128/jvi.67.12.7654-7658.1993
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Brady Beltrán Gárate
This work is licensed under a Creative Commons Attribution 4.0 International License.
